secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001193125-26-193957
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports Q1 net loss $69.2M; Gilead licenses KT-200 for $45M milestone
----------------------------------------------------------------------------

- Net loss $69.2M in Q1 2026, vs $65.6M in Q1 2025; cash $1.55B provides runway into 2029.
- Collaboration revenue $34.4M (all from Gilead), up from $22.1M in Q1 2025.
- Gilead exercised option to license KT-200 (oral CDK2 degrader), triggering a $45M milestone payment.
- KT-621 Phase 2b BROADEN2 (AD) data expected mid-2027; BREADTH (asthma) data late 2027; FDA Fast Track for asthma.
- KT-579 Phase 1 healthy volunteer trial ongoing; data expected in 2H26; KT-485/SAR447971 IND complete, clinical entry 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/0001193125-26-193957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/kymr-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-193957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer